dorfmanmaster

Gilead in tested channel

做多
NASDAQ:GILD   Gilead Sciences, Inc.
GILD has seen positive price action YTD; due to combatting the COVID-19 with their drug Remdesivir.

Yesterday on the news, the trial on humans which was set in China to prove the effectivity of the drug, apparently "failed". However... The price just took us to the lower part of the channel, meaning the Risk-Reward-Ratio is at a good stance.

A close below the 50sma would change the sentiment, and remove us from the channel.

免责声明

这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。